Novo Nordisk continues to expand its Wegovy franchise in the obesity market, with the oral version of Wegovy and higher‑dose injection both reinforcing its positioning despite an overall sales slowdown forecast for 2026.
Key developments include FDA approval of Wegovy HD (7.2 mg) and a rapidly growing partition of new prescriptions in the branded obesity market, where Wegovy now leads in new‑to‑brand share by about 65%.
The oral Wegovy pill has launched explosively in the U.S., with tens of thousands of weekly prescriptions and over hundreds of thousands of total prescriptions within its first months, and Novo has begun its first international rollout outside the U.S., starting with the UAE.
Despite facing stiffer competition from Eli Lilly and a projected 5–13% revenue decline in 2026, Novo’s obesity segment remains central to its strategy, with Wegovy contributing to sustained growth in new patient prescriptions and global GLP‑1 volumes.
Sources:
Novo Nordisk faces defining year in the obesity drug market - CNBC
Novo Nordisk A/S Q1 Earnings Call Highlights
Novo Nordisk's next obesity battlefront: Winning beyond America
Novo Nordisk Dominates Obesity Market as Wegovy Sales Soar 76%
Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment
FDA approves Novo Nordisk's new Wegovy® HD injection ...
Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch
Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.
Novo Nordisk shares tumble after company warns of sales hit this year
Novo Nordisk launches obesity drug Wegovy in China
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
Novo Nordisk Warns of First Sales Drop Since Start of Ozempic